Reagents and kits for diagnosing prostate cancer
By detecting the methylation level of specific gene regions, a non-invasive and efficient prostate cancer diagnosis method is provided, which solves the shortcomings in the diagnosis of early prostate cancer in the prior art, achieves high sensitivity and high specificity, and reduces overtreatment risk.
Patent Information
- Application Number
- CN202211172661.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-26
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-09-26
AI Technical Summary
The existing prostate cancer diagnosis methods have invasive manipulation, localized sampling, false negative and false positive results, resulting in low early diagnosis rate and excessive treatment, especially low specificity of serological PSA detection and insufficient sensitivity and specificity of imaging examinations. .
By detecting the methylation levels of Chr12:104458334-104458711, Chr2:200585783-200586029, Chr16:23835778-23836250 and Chr2:190180542-190181118 regions, methylation-specific PCR, bisulfite sequencing and other methods are provided. A reagent and kit for diagnosing prostate cancer, achieving non-invasive, high sensitivity and high specificity diagnosis.
The diagnosis of prostate cancer is achieved by non-invasive, high sensitivity and good specificity. The sensitivity of diagnosing prostate cancer can reach 86.96%, and the specificity in the blood samples of healthy people is 95.31%, reducing the risk of overtreatment.
Smart Images

Figure CN116287227B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of in vitro diagnostic reagents, and in particular to a reagent and a kit for diagnosing prostate cancer. Background Art
[0002] Prostate cancer is one of the most common malignant tumors of the male reproductive system. It has long threatened men's health. It is the second most common cancer in men and the fifth most deadly cancer. Because early prostate cancer usually has no obvious symptoms, patients are often already in the late stage when diagnosed. Therefore, screening for prostate cancer in the early stage in order to detect lesions and provide patients with the opportunity for curative treatment is an important means to benefit prostate cancer patients.
[0003] Currently, the commonly used diagnostic methods for prostate cancer in clinical practice include rectal examination, serological PSA (prostate-specific antigen) testing, imaging examinations, and pathological biopsy. Puncture biopsy and pathological examination of prostate lesions are the gold standard for diagnosing prostate cancer, but they are invasive procedures, sampling has limitations, and there is a risk of false negatives. Imaging examinations include prostate color Doppler ultrasound, magnetic resonance imaging, PET-CT, etc. The sensitivity and specificity of prostate color Doppler ultrasound detection are low; although magnetic resonance imaging is helpful for staging prostate cancer and understanding its metastasis, its detection rate for early prostate cancer is low. Serological PSA testing has low specificity, and in some patients with benign prostatic hyperplasia, it often has false positive results. The use of serological PSA screening methods may lead to the detection of more indolent cancers, resulting in adverse effects such as overtreatment. Summary of the invention
[0004] Based on this, it is necessary to provide a reagent for detecting the methylation level of the target area for use in the preparation of a diagnostic product for prostate cancer. By detecting the methylation levels in the regions of Chr12:104458334-104458711, Chr2:200585783-200586029, Chr16:23835778-23836250 and Chr2:190180542-190181118, non-invasive diagnosis can be achieved with good sensitivity and high specificity.
[0005] A reagent for detecting the methylation level of a target region is used in the preparation of a diagnostic product for prostate cancer, with GRCh38.p14 being used as a reference genome, wherein the target region includes one or more of the following regions: a partial region or the full length of the negative chain of Chr12:104458334-104458711; a partial region or the full length of the positive chain of Chr2:200585783-200586029; a partial region or the full length of the positive chain of Chr16:23835778-23836250; and a partial region or the full length of the positive chain of Chr2:190180542-190181118.
[0006] In one embodiment, the partial region of the negative chain of Chr12: 104458334-104458711 includes at least one of the following regions: CHST11-R1: the negative chain of Chr12: 104458602-104458711, CHST11-R2: the negative chain of Chr12: 104458559-104458682, and CHST11-R3: the negative chain of Chr12: 104458334-104458711. 104458472 negative chain; the partial region of the positive chain of Chr2: 200585783-200586029 includes at least one of the following regions: AOX1-R1: Chr2: 200585783-200585900 positive chain, and AOX1-R2: Chr2: 200585890-200586029 positive chain; the part of the positive chain of Chr16: 23835778-23836250 The region includes at least one of the following regions: PRKCB-R1: positive strand of Chr16: 23835778-23835919, PRKCB-R2: positive strand of Chr16: 23835959-23836062, and PRKCB-R3: positive strand of Chr16: 23836175-23836250; the partial region of the positive strand of Chr2: 190180542-190181118 includes the following region At least one of: C2orf88-R1: the positive strand of Chr2: 190180542-190180678, C2orf88-R2: the positive strand of Chr2: 190180686-190180825, C2orf88-R3: the positive strand of Chr2: 190180828-190180927, and C2orf88-R4: the positive strand of Chr2: 190180994-190181118.
[0007] In one embodiment, the target region includes CHST11-R3 and C2orf88-R1; or, the target region includes CHST11-R3 and PRKCB-R2; or, the target region includes CHST11-R3 and AOX1-R2; or, the target region includes AOX1-R2 and PRKCB-R2; or, the target region includes AOX1-R2 and C2orf88-R1; or, the target region includes PRKCB-R2 and C2orf88-R1; or, the target region includes or, the target region includes CHST11-R3, AOX1-R2 and PRKCB-R2; or, the target region includes CHST11-R3, AOX1-R2 and C2orf88-R1; or, the target region includes CHST11-R3, PRKCB-R2 and C2orf88-R1; or, the target region includes AOX1-R2, PRKCB-R2 and C2orf88-R1; or, the target region includes CHST11-R3, AOX1-R2, PRKCB-R2 and C2orf88-R1.
[0008] A reagent for diagnosing prostate cancer, the reagent is used to detect the methylation level of a target region, with GRCh38.p14 as a reference, the target region including one or more of the following regions: a partial region or the full length of the negative chain of Chr12:104458334-104458711; a partial region or the full length of the positive chain of Chr2:200585783-200586029; a partial region or the full length of the positive chain of Chr16:23835778-23836250; and a partial region or the full length of the positive chain of Chr2:190180542-190181118.
[0009] In one embodiment, the reagent detects the methylation level of the target area by one or more of the following methods: methylation-specific PCR, bisulfite sequencing, methylation-specific microarray, whole genome methylation sequencing, pyrophosphate sequencing, methylation-specific high-performance liquid chromatography, digital PCR, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method and methylation fluorescence quantitative PCR.
[0010] In one embodiment, the reagent includes one or more of the following primer pairs: a primer pair for detecting the full length or partial region of the negative chain of Chr12:104458602-104458711, a primer pair for detecting the full length or partial region of the negative chain of Chr12:104458559-104458682, a primer pair for detecting the full length or partial region of the negative chain of Chr12:104458334-104458472, a primer pair for detecting the full length or partial region of the positive chain of Chr2:200585783-200585900, a primer pair for detecting the full length or partial region of the positive chain of Chr2:200585890-200586029, a primer pair for detecting the full length or partial region of the positive chain of Chr16:23835778-23835919 Primer pairs for detecting the full length or a partial region of the positive chain of Chr16:23835959-23836062, and primer pairs for detecting the full length or a partial region of the positive chain of Chr16:23836175-23836250; primer pairs for detecting the full length or a partial region of the positive chain of Chr2:190180542-190180678, primer pairs for detecting the full length or a partial region of the positive chain of Chr2:190180686-190180825, primer pairs for detecting the full length or a partial region of the positive chain of Chr2:190180828-190180927, and primer pairs for detecting the full length or a partial region of the positive chain of Chr2:190180994-190181118.
[0011] In one embodiment, the reagent includes one or more of the following primer pairs: a primer pair with a nucleotide sequence as shown in SEQ ID NO: 1-2, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 3-4, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 5-6, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 7-8, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 9-10, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 11-12, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 13-14, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 15-16, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 17-18, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 19-20, a primer pair with a nucleotide sequence as shown in SEQ ID NO: 21-22, and a primer pair with a nucleotide sequence as shown in SEQ ID NO: 23-24.
[0012] In one embodiment, the reagent further comprises a detection probe corresponding to the primer pair;
[0013] Furthermore, the nucleotide sequence of the detection probe corresponding to the primer pair is selected from one of SEQ ID NOs: 25-36.
[0014] A kit for diagnosing prostate cancer, comprising the above-mentioned reagent for diagnosing prostate cancer.
[0015] In one embodiment, the kit includes one or more of a nucleic acid extraction reagent, a methylation conversion reagent, a quality control reagent, a PCR reaction reagent, and a sequencing reagent. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 is the methylation level of the specific regions of the CHST11 gene, AOX1 gene, PRKCB gene, and C2orf88 gene in prostate cancer tissues and normal tissues in Example 1;
[0017] Figure 2-3 ROC curves for diagnosing blood samples of prostate cancer patients and healthy subjects for each single target area in Example 3;
[0018] Figure 4-5 ROC curves for joint diagnosis of multiple target regions in blood samples of prostate cancer patients and healthy subjects. DETAILED DESCRIPTION
[0019] In order to facilitate understanding of the present application, the present application will be described more comprehensively below. The present application can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the disclosure of the present application more thorough and comprehensive.
[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.
[0021] It should be noted that, in this article, unless otherwise specified, the positions on the chromosome are all based on GRCh38.p14; in addition, because the DNA on the chromosome is a double-stranded structure composed of a positive strand and a negative strand, for a region represented by a chromosomal position, if it is not specified whether it is the positive strand or the negative strand of the DNA, it means that it can be the positive strand of the DNA in the region, the negative strand of the DNA in the region, or both the positive and negative strands of the DNA in the region. For example, if the region Chr12:104458334-104458711 is described as "Chr12:104458334-104458711", it means that it can be the positive strand of the DNA in the region Chr12:104458334-104458711, it can be the negative strand of the DNA in the region Chr12:104458334-104458711, or it can be both the positive and negative strands of the DNA in the region Chr12:104458334-104458711. If the region Chr12:104458334-104458711 is described as "the plus strand of Chr12:104458334-104458711", it means the plus strand of DNA in the region Chr12:104458334-104458711. If the region Chr12:104458334-104458711 is described as "the minus strand of Chr12:104458334-104458711", it means the minus strand of DNA in the region Chr12:104458334-104458711.
[0022] The term "and / or" or "and / or" refers to any and all combinations of one or more of the associated listed items.
[0023] The term "plurality" means more than two; "multiple" means more than two; and "above" when combined with a number to express a quantity includes the number itself, for example "more than two" includes two.
[0024] The term "prostate cancer" refers to an epithelial malignant tumor that occurs in the prostate. In 2004, WHO's "Pathology and Genetics of Tumors of the Urinary System and Male Reproductive Organs" listed prostate cancer pathological types as adenocarcinoma (acinar adenocarcinoma), ductal adenocarcinoma, urothelial carcinoma, squamous cell carcinoma, and adenosquamous carcinoma, of which prostate adenocarcinoma accounts for more than 95%.
[0025] The term "diagnosis" includes auxiliary diagnosis, recurrence risk assessment, assessment of cancer risk and degree, and prognosis.
[0026] The term "oligonucleotide" or "polynucleotide" or "nucleotide" or "nucleic acid" refers to a molecule having two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. Oligonucleotides can be produced in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof. The typical deoxyribonucleotides of DNA are thymine, adenine, cytosine, and guanine. The typical ribonucleotides of RNA are uracil, adenine, cytosine, and guanine.
[0027] The term "methylation" is a form of chemical modification of DNA that can change genetic expression without changing the DNA sequence. DNA methylation refers to the covalent attachment of a methyl group to the 5th carbon position of cytosine in genomic CpG dinucleotides under the action of DNA methyltransferase. DNA methylation can cause changes in chromatin structure, DNA conformation, DNA stability, and the way DNA interacts with proteins, thereby controlling gene expression.
[0028] The term "methylation level" refers to whether the cytosine in one or more CpG dinucleotides in a DNA sequence is methylated, or the frequency / proportion / percentage of methylation, which represents both qualitative and quantitative concepts. In practical applications, different detection indicators can be used to compare DNA methylation levels according to actual conditions. For example, in some cases, the comparison can be based on the Ct value of the sample test; in some cases, the proportion of gene methylation in the sample can be calculated, that is, the number of methylated molecules / (the number of methylated molecules + the number of unmethylated molecules) × 100, and then compared; in some cases, it is also necessary to statistically analyze and integrate the various indicators to obtain the final judgment indicator.
[0029] The term "primer" refers to an oligonucleotide that can be used in an amplification method (e.g., polymerase chain reaction, PCR) to amplify a target sequence based on a polynucleotide sequence corresponding to a target gene or a portion thereof. Typically, at least one of the PCR primers used to amplify a polynucleotide sequence is sequence-specific for the polynucleotide sequence. The exact length of the primer depends on many factors, including temperature, primer source, and the method used. For example, for diagnostic and prognostic applications, oligonucleotide primers typically contain at least 10, 15, 20, 25 or more nucleotides, but may also contain fewer nucleotides, depending on the complexity of the target sequence.
[0030] The term "primer pair" refers to a pair of primers that can hybridize to double strands of a target DNA molecule or to regions of a target DNA molecule that are located on both sides of a nucleotide sequence to be amplified.
[0031] The term "Taqman probe" refers to an oligonucleotide sequence containing a 5' fluorescent group and a 3' quencher group. When the probe binds to the corresponding site on the DNA, the probe will not emit fluorescence because of the presence of a quencher group near the fluorescent group. During the amplification process, if the probe binds to the amplified chain, the 5' to 3' exonuclease activity of the DNA polymerase (such as Taq enzyme) will digest the probe, and the fluorescent group will be away from the quencher group, and its energy will not be absorbed, thus generating a fluorescent signal. After each PCR cycle, the fluorescent signal also has a synchronous exponential growth process like the target fragment.
[0032] One embodiment of the present application provides an application of a reagent for detecting the methylation level of a target gene in the preparation of a diagnostic product for prostate cancer. Specifically, the target gene includes at least one of the human CHST11 gene (Gene ID in the NCBI database: 50515, the same below), the human AOX1 gene (Gene ID in the NCBI database: 316, the same below), the human PRKCB gene (Gene ID in the NCBI database: 5579, the same below) and the human C2orf88 gene (Gene ID in the NCBI database: 84281, the same below).
[0033] In some embodiments, the target gene includes human CHST11 gene and human PRKCB gene. In other embodiments, the target gene includes human CHST11 gene, human PRKCB gene and human AOX1 gene. In other embodiments, the target gene includes human CHST11 gene, human PRKCB gene and human C2orf88 gene. In some embodiments, the target gene includes human CHST11 gene, human PRKCB gene and human AOX1 gene, C2orf88 gene.
[0034] Furthermore, the present application has found through research that there are significant differences in the methylation levels between prostate cancer tissue and normal prostate tissue in the Chr12:104458334-104458711, Chr2:200585783-200586029, Chr16:23835778-23836250 and Chr2:190180542-190181118 regions. The above four regions can be used as potential markers for diagnosing prostate cancer, and it has been verified that when diagnosing prostate cancer by detecting the partial or full-length methylation levels of any of the above regions, the specificity and sensitivity are high, and non-invasive diagnosis can be achieved. Based on this, one embodiment of the present application provides an application of a reagent for detecting the methylation level of a target region in the preparation of a diagnostic product for prostate cancer, taking GRCh38.p14 as a reference genome, the target region includes one or more of the following regions: a partial region or the full length of the negative chain of Chr12:104458334-104458711; a partial region or the full length of the positive chain of Chr2:200585783-200586029; a partial region or the full length of the positive chain of Chr16:23835778-23836250; and a partial region or the full length of the positive chain of Chr2:190180542-190181118.
[0035] Specifically, Chr12:104458334-104458711 is a partial region of the human CHST11 gene; Chr2:200585783-200586029 is a partial region of the human AOX1 gene; Chr16:23835778-23836250 is a partial region of the human PRKCB gene; Chr2:190180542-190181118 is a partial region of the human C2orf88 gene.
[0036] In some embodiments, the target region includes a partial region or full length of the negative strand of Chr12: 104458334-104458711 and a partial region or full length of the positive strand of Chr16: 23835778-23836250. In other embodiments, the target region includes a partial region or full length of the negative strand of Chr12: 104458334-104458711, a partial region or full length of the positive strand of Chr2: 200585783-200586029, and a partial region or full length of the positive strand of Chr16: 23835778-23836250. In other embodiments, the target region includes a partial region or the full length of the negative chain of Chr12: 104458334-104458711, a partial region or the full length of the positive chain of Chr16: 23835778-23836250, and a partial region or the full length of the positive chain of Chr2: 190180542-190181118. In other embodiments, the target region includes a partial region or the full length of the negative chain of Chr12: 104458334-104458711, a partial region or the full length of the positive chain of Chr2: 200585783-200586029, a partial region or the full length of the positive chain of Chr16: 23835778-23836250, and a partial region or the full length of the positive chain of Chr2: 190180542-190181118.
[0037] In some embodiments, the DNA fragment lengths of the partial region of the negative strand of Chr12:104458334-104458711, the partial region of the positive strand of Chr2:200585783-200586029, the partial region of the positive strand of Chr16:23835778-23836250, and the partial region of the positive strand of Chr2:190180542-190181118 are 80 bp to 160 bp. Furthermore, the DNA fragment lengths of the partial region of the negative chain of Chr12:104458334-104458711, the partial region of the positive chain of Chr2:200585783-200586029, the partial region of the positive chain of Chr16:23835778-23836250, and the partial region of the positive chain of Chr2:190180542-190181118 are 100 bp to 150 bp.
[0038] In some embodiments, the partial region of the negative strand of Chr12: 104458334-104458711 includes at least one of the following regions: CHST11-R1: the negative strand of Chr12: 104458602-104458711, CHST11-R2: the negative strand of Chr12: 104458559-104458682, and CHST11-R3: the negative strand of Chr12: 104458334-104458472.
[0039] In some embodiments, the partial region of the positive strand of Chr2:200585783-200586029 includes at least one of the following regions: the positive strand of AOX1-R1:Chr2:200585783-200585900, and the positive strand of AOX1-R2:Chr2:200585890-200586029.
[0040] In some embodiments, the partial region of the positive strand of Chr16:23835778-23836250 includes at least one of the following regions: PRKCB-R1: the positive strand of Chr16:23835778-23835919, PRKCB-R2: the positive strand of Chr16:23835959-23836062, and PRKCB-R3: the positive strand of Chr16:23836175-23836250.
[0041] In some embodiments, the partial region of the positive strand of Chr2: 190180542-190181118 includes at least one of the following regions: C2orf88-R1: the positive strand of Chr2: 190180542-190180678, C2orf88-R2: the positive strand of Chr2: 190180686-190180825, C2orf88-R3: the positive strand of Chr2: 190180828-190180927, and C2orf88-R4: the positive strand of Chr2: 190180994-190181118.
[0042] Further, the target region includes CHST11-R3 and C2orf88-R1; or, the target region includes CHST11-R3 and PRKCB-R2; or, the target region includes CHST11-R3 and AOX1-R2; or, the target region includes AOX1-R2 and PRKCB-R2; or, the target region includes AOX1-R2 and C2orf88-R1; or, the target region includes PRKCB-R2 and C2orf88-R1; or, the target region includes CHST 11-R3, AOX1-R2 and PRKCB-R2; alternatively, the target region includes CHST11-R3, AOX1-R2 and C2orf88-R1; alternatively, the target region includes CHST11-R3, PRKCB-R2 and C2orf88-R1; alternatively, the target region includes AOX1-R2, PRKCB-R2 and C2orf88-R1; alternatively, the target region includes CHST11-R3, AOX1-R2, PRKCB-R2 and C2orf88-R1.
[0043] Based on the above, one embodiment of the present application further provides a kit for diagnosing prostate cancer, the kit comprising a reagent for detecting the methylation level of any of the above target regions.
[0044] Optionally, the above-mentioned reagent for diagnosing prostate cancer realizes the detection of the methylation level of the target area by one or more of the following methods: methylation-specific PCR, bisulfite sequencing, methylation-specific microarray, whole genome methylation sequencing, pyrophosphate sequencing, methylation-specific high-performance liquid chromatography, digital PCR, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method and methylation fluorescence quantitative PCR. Accordingly, the reagent necessary for the above-mentioned method for detecting the methylation level is included in the kit. It is to be understood that, in other embodiments, the method for detecting the methylation level of the target area by the above-mentioned reagent for diagnosing prostate cancer is not limited to the above. In addition, it should be noted that, herein, "optionally" means giving an example.
[0045] In some embodiments, the reagent detects the methylation level of the target region by methylation-specific fluorescence quantitative method (qMSP). Optionally, the reagent includes a primer pair for detecting any of the target regions. Further, the above reagents include one or more of the following primer pairs: a primer pair for detecting the full length or partial region of the negative chain of Chr12:104458602-104458711, a primer pair for detecting the full length or partial region of the negative chain of Chr12:104458559-104458682, a primer pair for detecting the full length or partial region of the negative chain of Chr12:104458334-104458472, a primer pair for detecting the full length or partial region of the positive chain of Chr2:200585783-200585900, a primer pair for detecting the full length or partial region of the positive chain of Chr2:200585890-200586029, a primer pair for detecting the positive chain of Chr16:23835778-23835919 Primer pairs for detecting the full length or partial region of the positive chain of Chr16:23835959-23836062, and primer pairs for detecting the full length or partial region of the positive chain of Chr16:23836175-23836250; primer pairs for detecting the full length or partial region of the positive chain of Chr2:190180542-190180678, primer pairs for detecting the full length or partial region of the positive chain of Chr2:190180686-190180825, primer pairs for detecting the full length or partial region of the positive chain of Chr2:190180828-190180927, and primer pairs for detecting the full length or partial region of the positive chain of Chr2:190180994-190181118.
[0046] Furthermore, the above-mentioned reagents include one or more of the following primer pairs: a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 1 to 2, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 3 to 4, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 5 to 6, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 7 to 8, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 9 to 10, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 11 to 12, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 13 to 14, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 15 to 16, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 17 to 18, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 19 to 20, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 21 to 22, and a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 23 to 24.
[0047] In some embodiments, the above reagents further include a detection probe corresponding to the primer pair. Optionally, the nucleotide sequence of the detection probe corresponding to the primer pair is selected from one of SEQ ID NOs: 25 to 36. It is understood that the specific nucleotide sequences of the primer pair and the detection probe used to detect any of the above regions are not limited to the above, and can also be other nucleotide sequences designed according to the target region to be detected.
[0048] In some embodiments, the above reagents also include an internal reference primer pair and a detection probe corresponding to the internal reference primer pair. Optionally, the internal reference primer pair includes an ACTB primer pair designed for the ACTB gene. In an optional specific example, the nucleotide sequence of the ACTB primer pair is shown in SEQ ID NOs: 37-38, and the nucleotide sequence of the detection probe corresponding to the ACTB primer pair is shown in SEQ ID NO: 39. It is understandable that in other embodiments, other genes can also be selected as internal reference genes. In this case, the internal reference primer pair and the internal reference probe can be designed accordingly.
[0049] Optionally, a fluorescent group is connected to the detection probe. In certain embodiments, the detection probe is a Taqman probe. Further, a fluorescent group and a quencher group are connected to the detection probe. Optionally, the fluorescent group is located at the 5' end of the probe, and the quencher group is located at the 3' end of the probe. Optionally, the fluorescent groups connected to the detection probe are independently selected from one of FAM, HEX, VIC, CY5, ROX, Texsa Red, JOE and Quasar 705. Of course, when there are more than two probes in the same reaction system, the fluorescent groups connected to different probes are different. It is understandable that the fluorescent groups connected to the detection probe of the target region and the detection probe of the internal reference gene are not limited to the above, and can also be other fluorescent groups.
[0050] In addition, one embodiment of the present application further provides a kit for diagnosing prostate cancer, wherein the kit comprises the reagent for diagnosing prostate cancer of any of the above embodiments.
[0051] In some embodiments, the above-mentioned kit further includes one or more of a nucleic acid extraction reagent, a methylation conversion reagent, a quality control reagent, a PCR reaction reagent, and a sequencing reagent. The nucleic acid extraction reagent is used to extract nucleic acid; the methylation conversion reagent is used to deaminize the unmethylated cytosine in DNA into uracil, while the methylated cytosine remains unchanged; the quality control reagent is used for quality control, such as positive quality control products and negative quality control products; the PCR reaction reagent is used to construct a PCR amplification reaction system; and the nucleic acid sequencing reagent is used for sequencing.
[0052] The above-mentioned kit for diagnosing prostate cancer diagnoses prostate cancer by detecting the methylation level of the target area, with a sensitivity of up to 86.96% and a specificity of 95.31% in healthy human blood samples.
[0053] In addition, an embodiment of the present application also provides a method for diagnosing prostate cancer, which diagnoses prostate cancer by detecting the methylation level of the target region of any of the above embodiments.
[0054] In some embodiments, the above-mentioned diagnostic method uses the reagent for diagnosing prostate cancer of any of the above-mentioned embodiments or the kit for diagnosing prostate cancer of any of the above-mentioned embodiments to detect the methylation level of any of the above-mentioned target regions of the sample to be tested (such as a blood sample, urine sample or tissue sample of the subject to be tested), and determines whether the sample to be tested is a prostate cancer-positive sample based on the methylation level of the target region.
[0055] Furthermore, the above-mentioned diagnostic method includes step S10, step S20 and step S30. Specifically:
[0056] Step S10: extracting, transforming and purifying DNA from the sample to be tested.
[0057] Step S20: Mix the transformed and purified DNA with the nucleic acid product of any of the above embodiments and perform a methylation fluorescence quantitative PCR reaction.
[0058] Step S30: predicting whether the sample to be tested is a prostate cancer positive sample according to the qPCR result.
[0059] In some embodiments, the CHST11-R3 region and the C2orf88-R1 region are used as target regions for joint diagnosis. When the CHST11-R3 region and the C2orf88-R1 region are used for joint diagnosis, the formula for predicting the probability (P) that the sample to be tested is a prostate cancer positive sample is: ln(P / (1-P))=10.518+(-0.29)*ΔCt(CHST11-R3)+(-0.383)*ΔCt(C2orf88-R1); at this time, the threshold is 0.20. When the P of the sample to be tested is greater than or equal to 0.20, the sample to be tested is a prostate cancer positive sample; when the P of the sample to be tested is less than 0.20, the sample to be tested is a prostate cancer negative sample.
[0060] In some embodiments, CHST11-R3, AOX1-R2 and C2orf88-R1 are used as target regions for joint diagnosis. When CHST11-R3, AOX1-R2 and C2orf88-R1 are used for joint diagnosis, the formula for predicting the probability (P) that the sample to be tested is a prostate cancer positive sample is: ln(P / (1-P))=10.882+(-0.227)*ΔCt(CHST11-R3)+(-0.156)*ΔCt(AOX1-R2)+(-0.313)*ΔCt(C2orf88-R1); at this time, the threshold is 0.27. When the P of the sample to be tested is greater than or equal to 0.27, the sample to be tested is a prostate cancer positive sample; when the P of the sample to be tested is less than 0.27, the sample to be tested is a prostate cancer negative sample.
[0061] In some embodiments, CHST11-R3, AOX1-R2, PRKCB-R2 and C2orf88-R1 are used for joint diagnosis. When CHST11-R3, AOX1-R2, PRKCB-R2 and C2orf88-R1 are used for joint diagnosis, the formula for predicting the probability (P) that the sample to be tested is a prostate cancer positive sample is: ln(P / (1-P))=12.808+(-0.268)*ΔCt(CHST11-R3)+(-0.285)*ΔCt(AOX1-R2)+(-0.003)*ΔCt(PRKCB-R2)+(-0.251)*ΔCt(C2orf88-R1); at this time, the threshold is 0.26. When the P value of the sample to be tested is greater than or equal to 0.26, the sample to be tested is a prostate cancer positive sample; when the P value of the sample to be tested is less than 0.26, the sample to be tested is a prostate cancer negative sample.
[0062] It should be noted that in each of the above formulas, the ΔCt value is the difference between the Ct value of the target gene and the internal reference gene (eg, ACTB).
[0063] The above-mentioned prostate cancer diagnosis method is a non-invasive diagnosis method with good sensitivity. Its sensitivity in diagnosing prostate cancer can reach 86.96%, and its specificity in healthy human blood samples is 95.31%.
[0064] In addition, an embodiment of the present application further provides a predictive analysis device for prostate cancer, which includes: a calculation and analysis module and a data module.
[0065] Specifically, the calculation and analysis module is used to calculate the probability that the sample to be tested is a prostate cancer positive sample based on the methylation level of the target area of the sample to be tested, and predict whether the sample to be tested is a prostate cancer positive sample based on the probability and the preset value. The target area of the sample to be tested is the target area defined in the application of the reagent for detecting the methylation level of the target area in any of the above embodiments in the preparation of a diagnostic product for prostate cancer. The data module is used to provide the calculation and analysis module with the methylation level of the target area of the sample to be tested. It is understandable that, in some embodiments, the calculation and analysis module also has an output display unit for outputting the analysis result as a human recognizable language. Further, the formula for calculating the probability that the sample to be tested is a prostate cancer positive sample is as described above, and will not be repeated here.
[0066] It is understandable that each module in the above-mentioned prostate cancer prediction and analysis device can be implemented in whole or in part by software, hardware, or a combination thereof. Each of the above-mentioned modules can be embedded in or independent of a processor in a computer device in the form of hardware, or can be stored in a memory in a computer device in the form of software, so that the processor can call and execute operations corresponding to each of the above modules.
[0067] In addition, an embodiment of the present application further provides a computer device, including a memory and a processor, wherein the memory stores a computer program, and when the processor executes the computer program, the steps of the prostate cancer diagnosis method of any of the above embodiments are implemented.
[0068] It is understandable that the above-mentioned computer device can be a terminal. The computer device includes a processor, a memory, a communication interface, a display screen and an input device connected through a system bus. Among them: the processor of the computer device is used to provide computing and control capabilities. The memory of the computer device includes a non-volatile storage medium and an internal memory. The non-volatile storage medium stores an operating system and a computer program. The internal memory provides an environment for the operation of the operating system and the computer program in the non-volatile storage medium. The communication interface of the computer device is used to communicate with an external terminal in a wired or wireless manner. The wireless method can be implemented through WIFI, a mobile cellular network, NFC (near field communication) or other technologies. When the computer program is executed by the processor, a method for calculating a vascular inflammation-related risk index is implemented. The display screen of the computer device can be a liquid crystal display screen or an electronic ink display screen, and the input device of the computer device can be a touch layer covered on the display screen, or a button, a trackball or a touchpad set on the computer device housing, or an external keyboard, touchpad or mouse, etc.
[0069] In addition, an embodiment of the present application further provides a computer-readable storage medium storing a computer program, which, when executed by a processor, implements the steps of the method for diagnosing prostate cancer of any of the above embodiments.
[0070] In addition, an embodiment of the present application further provides a computer program product or a computer program, the computer program product or the computer program includes a computer instruction, and the computer instruction is stored in a computer-readable storage medium. The processor of the computer device reads the computer instruction from the computer-readable storage medium, and the processor executes the computer instruction, so that the computer device performs the steps of the prostate cancer diagnosis method of any of the above embodiments. Specific embodiments
[0072] The following is a detailed description in conjunction with specific examples. The following examples do not include other components except for inevitable impurities unless otherwise specified. The reagents and instruments used in the examples are conventionally selected in the art unless otherwise specified. The experimental methods for which specific conditions are not specified in the examples are implemented according to conventional conditions, such as the conditions described in the literature, books, or methods recommended by the manufacturer.
[0073] Example 1 Methylation status of CHST11, AOX1, PRKCB and C2orf88 gene regions in normal prostate tissue and prostate cancer tissue
[0074] The methylation sequencing data of Illumina 450K chip were downloaded from the TCGA database to analyze the methylation status of specific regions of CHST11, AOX1, PRKCB and C2orf88 genes in normal prostate tissues and prostate cancer tissues. Using GRCh38.p14 as the reference genome, the selected region of CHST11 gene was Chr12:104458334-104458711, the selected region of AOX1 gene was Chr2:200585783-200586029, the selected region of PRKCB gene was Chr16:23835778-23836250, and the selected region of C2orf88 gene was Chr2:190180542-190181118. The methylation level of the gene in the selected region is expressed as the average of the β values of all probes that recognize the region. The average methylation level of each gene in the selected region in normal prostate tissues and prostate cancer tissues was calculated. The results are shown in the figure. Figure 1 As shown, Figure 1 The statistical method used was the unpaired student t test.
[0075] from Figure 1It can be seen that the specific regions of CHST11, AOX1, PRKCB and C2orf88 genes are highly methylated in prostate cancer tissue samples (average β>0.4) and low methylated in normal prostate tissues (average β<0.2). The methylation levels of the four specific regions of genes in prostate cancer tissues are significantly higher than those in normal prostate tissues. Based on the differences in methylation levels of the specific regions of CHST11, AOX1, PRKCB and C2orf88 genes in prostate cancer tissues and normal prostate tissue samples, it is speculated that these four genes (regions shown) may be used as potential markers for diagnosing prostate cancer.
[0076] Example 2 Detection of methylation levels in specific regions of CHST11, AOX1, PRKCB and C2orf88 genes by methylation-specific fluorescence quantitative method (qMSP)
[0077] Using GRCh38.p14 as the reference genome, the negative-strand DNA molecules of the CHST11 gene located in the Chr12:104458334-104458711 region, the positive-strand DNA molecules of the AOX1 gene located in the Chr2:200585783-200586029 region, the positive-strand DNA molecules of the PRKCB gene located in the Chr16:23835778-23836250 region, and the positive-strand DNA molecules of the C2orf88 gene located in the Chr2:190180542-190181118 region as the target regions, methylation primer pairs and detection probes suitable for fluorescence quantitative PCR amplification were designed to amplify target fragments with a length of 80 to 160 bp to adapt to the detection of free DNA in blood or urine samples. The specific experimental steps include:
[0078] 1. Sample DNA Extraction
[0079] Anticoagulated blood samples were collected and centrifuged to obtain the upper plasma for extraction of plasma free DNA. Plasma cfDNA was extracted using the magnetic bead serum / plasma free DNA (cfDNA) extraction kit (DP709) from Tiangen Biochemical Technology (Beijing) Co., Ltd. The specific operation was carried out according to the kit instructions.
[0080] 2. Transformation and Purification of Sample DNA
[0081] The kits used for conversion and purification of sample DNA are all nucleic acid conversion reagents from Wuhan Aimisen Life Science Technology Co., Ltd. (Ehan Medical No. 20200843). For specific operation steps, please refer to the kit instructions.
[0082] 3. Methylation-specific fluorescence quantitative PCR
[0083] 1) Design of methylation primer pairs and detection probes:
[0084] Using the bisulfite-converted sequences of the target regions of each gene as templates, methylation primer pairs and detection probes were designed to amplify the corresponding regions of the target genes. Specifically, for the negative-strand DNA molecules of the CHST11 gene located in the Chr12:104458334-104458711 region, a total of 3 pairs of methylation primer pairs and detection probes were designed to amplify different regions; for the positive-strand DNA molecules of the AOX1 gene located in the Chr2:200585783-200586029 region, a total of 2 pairs of methylation primer pairs and detection probes were designed to amplify different regions; for the positive-strand DNA molecules of the PRKCB gene located in the Chr16:23835778-23836250 region, a total of 3 pairs of methylation primer pairs and detection probes were designed to amplify different regions; for the positive-strand DNA molecules of the C2orf88 gene located in the Chr2:190180542-190181118 region, a total of 4 pairs of methylation primer pairs and detection probes were designed to amplify different regions. The DNA sequences at the designated positions of each gene and the sequences after bisulfite conversion are shown in Table 1 , the sequences of the methylation primer pairs and detection probes used to amplify different target regions of each gene are shown in Table 2 , and the methylated cytosine sites that can be detected by the methylation primer pairs and detection probes are shown in Table 3 .
[0085] Table 1 Nucleotide sequences at specified positions of CHST11, AOX1, PRKCB, and C2orf88 genes and sequences after bisulfite conversion
[0086]
[0087]
[0088] Table 2 Nucleotide sequences of detection primer pairs and detection probes
[0089]
[0090]
[0091] Table 3 Methylated cytosine sites that can be detected by primer pairs and probes
[0092]
[0093]
[0094] 2) PCR amplification:
[0095] The methylation fluorescence quantitative PCR reaction system was prepared according to the formula in Table 4. The primer pairs and detection probes used in the reaction system were synthesized by Shanghai Shenggong Biotechnology Co., Ltd. The template used was DNA extracted from various samples and converted by bisulfite. Other components were purchased from Invitrogen (Cat: 14966005). In each PCR tube, in addition to the primer pairs and detection probes of the target region, the primer pairs and detection probes of the internal reference gene ACTB were also added. The upstream amplification primer of the internal reference gene ACTB was: AAGGTGGTTGGGTGGTTGTTTTG (SEQ ID NO: 37), the downstream amplification primer was: AATAACACCCCACCCTGC (SEQ ID NO: 38), and the detection probe was: GGAGTGGTTTTTGGGTTTG (SEQ ID NO: 39). The above detection probes are all TaqMan probes, the fluorescence reporter group at the 5' end of the detection probe of the target region is FAM, the fluorescence quencher group at the 3' end is MGB, the fluorescence reporter group at the 5' end of the detection probe of the ACTB gene is VIC, and the fluorescence quencher group at the 3' end is BHQ-1. After the PCR reaction system is prepared, amplification is performed according to the reaction program shown in Table 5.
[0096] Table 4 qMSP reaction system
[0097]
[0098] Table 5 qMSP reaction procedure
[0099]
[0100] When performing qPCR reaction to detect samples, it is necessary to set up negative and positive controls at the same time to ensure that the experimental system is reliable. Negative control tube: The PCR reaction system is configured according to the formula in Table 4, but the template is TE buffer. Positive control tube: The PCR reaction system is configured according to the formula in Table 4, but the template is an artificially synthesized plasmid containing ACTB (converted sequence) and the target region (converted sequence). Preparation method of positive control template: Clone the sequence of ACTB gene converted by bisulfite and the sequence of each target region converted by bisulfite into pUC57 to form an artificially synthesized plasmid, and dilute each plasmid to 10 3 Copies / μl. For example, the positive control template of CHST11-R1 is: 10 3 copies / μl of the plasmid containing the ACTB gene after transformation and 10 3 The copies / μl of the plasmid containing the CHST11-R1 sequence were mixed in a 1:1 ratio.
[0101] Ct value reading: After the qPCR reaction is completed, the baseline can be adjusted manually, and the fluorescence intensity value corresponding to 10 times the standard deviation of the baseline fluorescence value is set as the threshold. The threshold line is a straight line passing through the threshold and parallel to the X-axis, which must be within the exponential amplification period. The cycle number corresponding to the intersection of the threshold line and the amplification curve is the Ct value.
[0102] Quality control: The negative control should have no amplification, the positive control should have an obvious exponential growth period, and the Ct value of the positive control should be between 26 and 30. The Ct value of the internal reference gene of the sample to be tested should be ≤33. If the negative control, positive control and internal reference gene meet the above requirements, it indicates that this experiment is valid and the next step of sample result determination can be carried out. Otherwise, the experiment is invalid and must be retested.
[0103] 4.qMSP results analysis
[0104] Define ΔCt = Ct (target region) - Ct (ACTB), calculate the ΔCt value of each target region amplified in all samples, and then use IBMSPSS22.0 software to perform receiver operating curve characteristic (ROC) analysis. According to the ROC analysis results, the ΔCt when the Youden index (sensitivity + specificity - 1) is the largest is selected as the cutoff value. If the ΔCt value of the sample to be tested is less than or equal to the cutoff value, the sample is methylation-positive and the sample is a prostate cancer-positive sample; if the ΔCt value of the sample to be tested is greater than the cutoff value, the sample is methylation-negative and the sample is a prostate cancer-negative sample.
[0105] Example 3: Performance of qMSP method in diagnosing prostate cancer blood samples by detecting the methylation level of a single target region in a test sample
[0106] 1) Sample collection
[0107] Blood samples were collected from 142 patients diagnosed with prostate adenocarcinoma by tissue biopsy, and 160 healthy subjects as controls. The volume of each blood sample was greater than 8 mL. The collection process of all blood samples was approved by the ethics committee, all volunteers signed informed consent, and all samples were anonymized.
[0108] 2) The extraction, transformation and purification of free DNA in plasma samples were the same as in Example 2.
[0109] 3) qMSP detection and result analysis
[0110] 96 prostate adenocarcinoma blood samples and 96 healthy human blood samples were randomly selected as training sets, and the following tests and analyses were performed:
[0111] The primer pairs and probes provided in Example 2 were used to amplify the target regions of the CHST11, AOX1, PRKCB, and C2orf88 genes, respectively, and ROC analysis was performed based on the obtained ΔCt values. Specifically, the state variable of the prostate adenocarcinoma plasma sample was set to "1", and the state variable of the healthy person plasma sample was set to "0". Click "Analysis" - "ROC Curve Graph", specify the values of the test variable and the state variable, set the value of the state variable to 1, and select "Smaller test results indicate a clearer test" to obtain the ROC analysis results, select the ΔCt when the Youden index (sensitivity + specificity - 1) is the largest as the cutoff value, and obtain the average AUC value, sensitivity and specificity values. The results are shown in Table 6. The ROC curves of each target region are shown in Table 6. Figure 2-3 shown.
[0112] Table 6 Performance of each target area in detecting blood samples of prostate adenocarcinoma
[0113] Target area Sensitivity (%) Specificity (%) AUC value Cutoff value CHST11-R1 55.2 96.9 0.759 15.81 CHST11-R2 57.3 93.7 0.758 17.25 CHST11-R3 64.6 97.9 0.810 17.23 AOX1-R1 53.1 94.8 0.741 17.44 AOX1-R2 65.6 97.9 0.814 17.06 PRKCB-R1 50.0 93.7 0.719 17.20 PRKCB-R2 62.5 95.8 0.800 17.42 PRKCB-R3 47.9 93.7 0.709 16.76 C2orf88-R1 66.7 96.9 0.810 17.30 C2orf88-R2 58.3 92.7 0.758 17.42 C2orf88-R3 56.3 93.7 0.744 17.29 C2orf88-R4 55.2 90.6 0.725 17.45
[0114] As can be seen from Table 6, the effects of different regions of CHST11, AOX1, PRKCB and C2orf88 genes in detecting prostate adenocarcinoma are not exactly the same. Overall, all regions have a certain detection rate for prostate adenocarcinoma and a high specificity. The sensitivity of diagnosing prostate adenocarcinoma blood samples is above 47%, and the specificity of diagnosing healthy blood samples is higher than 90%. Specifically, the AUC values of each region of CHST11, AOX1, PRKCB and C2orf88 genes for diagnosing prostate cancer range from 0.725 to 0.814. Among them, when the target regions detected are CHST11-R3, AOX1-R2, PRKCB-R2, and C2orf88-R1, the diagnostic effect is better.
[0115] The remaining 46 prostate adenocarcinoma blood samples and 64 healthy human blood samples were selected as the test set, and the target regions of the CHST11, AOX1, PRKCB, and C2orf88 genes were amplified according to the primer pairs and probes provided in Example 2, and then the ΔCt values were calculated. In the test set, if the ΔCt value of the sample to be tested is less than or equal to the cutoff value, the sample is considered to be methylation positive, and then the sample is judged to be a cancer positive sample; if the ΔCt value of the sample to be tested is greater than the cutoff value, the sample is methylation negative, and then the sample is judged to be a cancer negative sample. The cutoff values of each target region are shown in Table 6. The performance of each target region in the test set for diagnosing prostate adenocarcinoma blood samples is shown in Table 7.
[0116] Table 7 Performance of each target area in detecting prostate adenocarcinoma blood samples
[0117]
[0118]
[0119] In the test set, the performance of each region in diagnosing prostate adenocarcinoma plasma samples was similar to that in the training set. When CHST11-R3, AOX1-R2, PRKCB-R2, and C2orf88-R1 were used as target regions, the sensitivity and specificity of diagnosis were slightly higher than those of other regions. The sensitivity of these four regions in detecting prostate adenocarcinoma plasma samples was higher than 63%, and the sensitivity of these four regions in detecting healthy human plasma samples was higher than 96%.
[0120] Example 4 Performance of qMSP method in detecting methylation levels of multiple target regions in a test sample and in diagnosing prostate adenocarcinoma blood samples
[0121] The data results of the training set in Example 3 are now used to analyze the effect of the combined diagnosis of prostate adenocarcinoma blood samples by the four regions of CHST11-R3, AOX1-R2, PRKCB-R2 and C2orf88-R1. In this embodiment, the effects of the combined diagnosis of regions from 2 genes, the combined diagnosis of regions from 3 genes, and the combined diagnosis of regions from 4 genes are analyzed respectively. The specific analysis method is: first, binary or multivariate Logistic analysis is performed on the ΔCt values of multiple regions to obtain a probability value, and then ROC analysis is performed using the probability value as the test variable. The software setting process is the same as the analysis process of the above-mentioned single detection region. The results are shown in Tables 8 and Figure 4-5 shown.
[0122] Table 8 Performance of multi-region combined diagnosis of prostate adenocarcinoma blood samples
[0123]
[0124] As can be seen from Table 8, the combination of CHST11-R3, AOX1-R2, PRKCB-R2 and C2orf88-R1 in any way is better than the single detection of a certain area. The AUC value of the diagnosis of prostate adenocarcinoma corresponding to any combination of these four areas is higher than 0.82. When two areas are diagnosed together, the combined diagnosis of CHST11-R3 and C2orf88-R1 has the best effect, with a sensitivity of 81.3%, a specificity of 93.7% and an AUC value of 0.913. When three areas are diagnosed together, the combined diagnosis of CHST11-R3, AOX1-R2 and C2orf88-R1 has the best effect, with a sensitivity of 82.3%, a specificity of 93.7% and an AUC value of 0.915. In addition, it can be seen from Table 8 that the combined diagnosis of prostate adenocarcinoma by the four regions has the best effect. The sensitivity of the combined diagnosis using the methylation levels of the four regions is 86.5%, the specificity is 93.7%, and the AUC value is 0.920. In summary, the combination of CHST11-R3, AOX1-R2, PRKCB-R2, and C2orf88-R1 as the target region can be used to effectively diagnose prostate adenocarcinoma by detecting its methylation level.
[0125] The 46 prostate adenocarcinoma blood samples and 64 healthy human blood samples in the test set of Example 3 were used as the test set of this example to verify the performance of the combined diagnosis of CHST11-R3 and C2orf88-R1, the combined diagnosis of CHST11-R3, AOX1-R2, and C2orf88-R1, and the combined diagnosis of prostate adenocarcinoma by CHST11-R3, AOX1-R2, PRKCB-R2, and C2orf88-R1. According to the logistic regression analysis, the equation related to the probability value P was obtained. When CHST11-R3 and C2orf88-R1 were used for joint diagnosis, the equation was: ln(P / (1-P))=10.518+(-0.29)*ΔCt(CHST11-R3)+(-0.383)*ΔCt(C2orf88-R1); when CHST11-R3, AOX1-R2, and C2orf88-R1 were used for joint diagnosis, the equation for the probability value P was: ln(P / (1-P))=10.882+(-0.227)*ΔCt(CHST11-R3)+(-0.156)*ΔC t(AOX1-R2)+(-0.313)*ΔCt(C2orf88-R1); when CHST11-R3, AOX1-R2, PRKCB-R2, and C2orf88-R1 were used for joint diagnosis, the equation for the probability value P was: ln(P / (1-P))=12.808+(-0.268)*ΔCt(CHST11-R3)+(-0.285)*ΔCt(AOX1-R2)+(-0.003)*ΔCt(PRKCB-R2)+(-0.251)*ΔCt(C2orf88-R1), where the ΔCt value was the difference between the Ct value of the target gene and the internal reference gene ACTB. According to the above equation, the probability values P of the two-region, three-region and four-region combined diagnosis test set samples are calculated respectively. If the P value is less than the cutoff value, it indicates that the sample is a healthy person sample. If the P value is greater than or equal to the cutoff value, it indicates that the sample is a prostate adenocarcinoma positive sample. The specific diagnosis results are shown in Table 9.
[0126] Table 9 Performance of multi-region combined diagnosis of prostate adenocarcinoma blood samples
[0127]
[0128] As can be seen from Table 9, in the test set, the two-region joint diagnosis, three-region joint diagnosis and four-region joint diagnosis of prostate adenocarcinoma blood samples are very effective. Specifically, when CHST11-R3 and C2orf88-R1 are jointly diagnosed, the sensitivity is 76.09% and the specificity is 96.88%; when CHST11-R3, AOX1-R2 and C2orf88-R1 are jointly diagnosed, the sensitivity is 80.43% and the specificity is 95.31%; when CHST11-R3, AOX1-R2, PRKCB-R2, C2orf88-R1 are jointly diagnosed, the sensitivity is 86.96% and the specificity is 95.31%. In summary, prostate cancer can be diagnosed by using the method of multi-gene region joint diagnosis.
[0129] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0130] The above-described embodiments only express several implementation methods of the present application, which is convenient for understanding the technical solutions of the present application in detail, but it cannot be understood as limiting the scope of protection of the patent application. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present application, several modifications and improvements can be made, which all belong to the scope of protection of the present application. It should be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the scope of protection of the claims attached to the present application. Therefore, the scope of protection of the patent of this application shall be based on the contents of the attached claims, and the description and drawings can be used to explain the contents of the claims.
Claims
1. Use of a reagent for detecting the methylation level of a target region in the preparation of a diagnostic product for prostate cancer, characterized in that: The reagents include a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 5 to 6 and a probe with a nucleotide sequence as shown in SEQ ID NO: 27, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 9 to 10 and a probe with a nucleotide sequence as shown in SEQ ID NO: 29, a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 13 to 14 and a probe with a nucleotide sequence as shown in SEQ ID NO: 31, and a primer pair with a nucleotide sequence as shown in SEQ ID NOs: 17 to 18 and a probe with a nucleotide sequence as shown in SEQ ID NO:
33.
2. A kit for diagnosing prostate cancer, characterized in that: The kit comprises the reagents described in claim 1.
3. The kit according to claim 2, characterized in that The kit also includes one or more of a nucleic acid extraction reagent, bisulfite, a quality control product or a PCR reaction reagent.
